Email this article The application of hbot with non-small lung cancer chemotherapy
- Authors: Popova MY1
-
Affiliations:
- Issue: Vol 14, No 1-2 (2014)
- Pages: 172-175
- Section: Articles
- URL: https://aspvestnik.ru/2410-3764/article/view/24566
- DOI: https://doi.org/10.17816/2072-2354.2014.0.1-2.172-175
- ID: 24566
Cite item
Full Text
Abstract
Carrying out chemotherapy is recommended to over 80% patients with non-small cell lung cancer (NSCLC). Chemotherapy side-effects force to reduce the dose of drugs, postponement of the next course of treatment or refuse treatment at all. That leads to worsen prognosis. It is an actual problem of neoteric oncology the search for new methods of correction of chemotherapy complications. Quite promising in this regard is the contemplation of Hyperbaric Oxygen Therapy (HBOT). In this study, we showed a reduction of hematologic toxicity in terms of hemoglobin, leukocytes, neutrophils and platelets in patients receiving chemotherapy scheme EP under HBOT sessions. The frequency and severity of chemotherapy toxicity were significantly less manifested.
References
- Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011; 61(2):69-90.
- Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108.
- Siegel R, Ward E, Brawley O, et al. Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61(4):212-236
- Bray F, Tyczynski JE, Parkin DM. Going up or coming down? The changing phases of the lung cancer epidemic from 1967 to 1999 in the 15 European Union countries. Eur J Cancer 2004; 40(1):96-125.
- Parkin DM, Pisani P, Lopez AD, et al. At least one in seven cases of cancer is caused by smoking. Global estimates for 1985. Int J Cancer. 1994; 59(4):494-504.
- Бычков М.Б. Немелкоклеточный рак лёгкого // Руководство по химиотерапии опухолевых заболеваний. / Под ред. Переводчиковой Н.И. - 3-е изд. - М.: Практическая медицина, 2011. - С. 141.
- Чиссов В.И. / Онкология: национальное руководство / Под ред. В.И. Чиссова, М.И. Давыдова // - М.: ГЭОТАР-Медиа, 2008. - С. 491.
- Ohguri T, Imada H, Narisada H, Yahara K, Morioka T, Nakano K, Miyaguni Y, Korogi Y. Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for non-small cell lung cancer with multiple pulmonary metastases: preliminary results. Int J Hyperthermia. 2009; 25: 160-167.
- Рак лёгкого: руководство, атлас / Трахтенберг А.Х., Чиссов. - М.: ГЕОТАР-Медиа, 2009. - 656с: ил. (стр. 39).
- Сommon Terminology Criteria for Adverse Events (CTCAE) Version 4.0 Published: May 28, 2009 (v4.03: June 14, 2010) U.S.DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health, National Cancer Institute.
- Моисеенко В.М. Лекарственное лечение распространённого немелкоклеточного рака лёгкого // Практическая онкология. - 2006. - Т. 7, №3. - С. 170-178.
- Тюляндитн С.А., Моисеенко В.М. / Практическая онкология: избранные лекции. - С-Пб.: Центр-ТОММ, 2004. - С. 291-297.
- Королева И.А., Копп М.В. Профилактика тошноты и рвоты при проведении цитостатической терапии у взрослых // Фарматека. - 2010. - №6. - С. 30-35.
- Способ лечения онкологических больных раком легких / С.В. Козлов, Ю.Г. Кутырева, М.Е. Попова и др. // Патент России на изобретение №2481091. - 2013. - Бюл. №13. - 5 с.
Supplementary files
